{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000103","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.150561+00:00","generated_at":"2026-05-17T03:02:43.745568+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA grants Type B meeting for Praxis's ulixacaltamide in Q4 2025","bullets":["FDA granted a Type B meeting following review of Essential3 topline results for ulixacaltamide.","Meeting to occur in Q4 2025; pre-NDA meeting request was previously disclosed.","Corporate presentation updated and posted on investors.praxismedicines.com.","No financial results or guidance changes included in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000103","json":"https://secwatch.observer/filing/0001689548-25-000103.json","markdown":"https://secwatch.observer/filing/0001689548-25-000103.md","text":"https://secwatch.observer/filing/0001689548-25-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/0001689548-25-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000103/prax-20251020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:02:43.745568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}